Investors frown on Fibrocell Science's public offering


Fibrocell Science (FCSC) slips after announcing a public offering with a 15% underwriter option.

Proceeds will go towards trials for new azficel-T indications — the cell-based product is currently approved for "smile lines". (PR)

Shares -14% premarket.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs